Literature DB >> 21415311

Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.

Sanjeev Sethi1, Fernando C Fervenza, Yuzhou Zhang, Samih H Nasr, Nelson Leung, Julie Vrana, Carl Cramer, Carla M Nester, Richard J H Smith.   

Abstract

BACKGROUND AND OBJECTIVES: dense deposit disease (DDD) is the prototypical membranoproliferative glomerulonephritis (MPGN), in which fluid-phase dysregulation of the alternative pathway (AP) of complement results in the accumulation of complement debris in the glomeruli, often producing an MPGN pattern of injury in the absence of immune complexes. A recently described entity referred to as GN with C3 deposition (GN-C3) bears many similarities to DDD. The purpose of this study was to evaluate AP function in cases of GN-C3. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Five recent cases of MPGN with extensive C3 deposition were studied. Renal biopsy in one case exhibited the classic findings of DDD. Three cases showed GN-C3 in the absence of significant Ig deposition; however, the classic hallmark of DDD-dense deposits along the glomerular basement membranes and mesangium-was absent. The remaining case exhibited features of both DDD and GN-C3.
RESULTS: Evidence of AP activation was demonstrable in all cases and included increased levels of soluble membrane attack complex (all cases), positive AP functional assays (four cases), and a positive hemolytic assay (one case). Autoantibodies were found to C3 convertase (two cases) and to factor H (one case). Factor H mutation screening identified the H402 allele (all cases) and a c.C2867T p.T956M missence mutation (one case). Laser microdissection and mass spectrometry of glomeruli of GN-C3 (two cases) showed a proteomic profile very similar to DDD.
CONCLUSIONS: These studies implicate AP dysregulation in a spectrum of rare renal diseases that includes GN-C3 and DDD.
Copyright © 2011 by the American Society of Nephrology

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21415311      PMCID: PMC3087765          DOI: 10.2215/CJN.07110810

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  24 in total

1.  A statistical model for identifying proteins by tandem mass spectrometry.

Authors:  Alexey I Nesvizhskii; Andrew Keller; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2003-09-01       Impact factor: 6.986

2.  The role of complement in cryoglobulin-induced immune complex glomerulonephritis.

Authors:  Marten Trendelenburg; Liliane Fossati-Jimack; Josefina Cortes-Hernandez; Daniel Turnberg; Margarita Lewis; Shozo Izui; H Terence Cook; Marina Botto
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

3.  Secondary membranoproliferative glomerulonephritis.

Authors:  H G Rennke
Journal:  Kidney Int       Date:  1995-02       Impact factor: 10.612

Review 4.  Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.

Authors:  Gerald B Appel; H Terence Cook; Gregory Hageman; J Charles Jennette; Michael Kashgarian; Michael Kirschfink; John D Lambris; Lynne Lanning; Hans U Lutz; Seppo Meri; Noel R Rose; David J Salant; Sanjeev Sethi; Richard J H Smith; William Smoyer; Hope F Tully; Sean P Tully; Patrick Walker; Michael Welsh; Reinhard Würzner; Peter F Zipfel
Journal:  J Am Soc Nephrol       Date:  2005-03-30       Impact factor: 10.121

5.  Dense deposit disease associated with monoclonal gammopathy of undetermined significance.

Authors:  Sanjeev Sethi; William R Sukov; Yuzhou Zhang; Fernando C Fervenza; Donna J Lager; Dylan V Miller; Lynn D Cornell; Srivilliputtur G Santhana Krishnan; Richard J H Smith
Journal:  Am J Kidney Dis       Date:  2010-09-15       Impact factor: 8.860

6.  Mesangiocapillary glomerulonephritis associated with meningococcal meningitis, C3 nephritic factor and persistently low complement C3 and C5.

Authors:  S A Hulton; R A Risdon; M J Dillon
Journal:  Pediatr Nephrol       Date:  1992-05       Impact factor: 3.714

7.  Incorporation of SP-40,40 into the soluble membrane attack complex (SMAC, SC5b-9) of complement.

Authors:  N H Choi; Y Nakano; T Tobe; T Mazda; M Tomita
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

8.  Hepatitis C virus infection and membranoproliferative glomerulonephritis in Japan.

Authors:  H Yamabe; R J Johnson; D R Gretch; K Fukushi; H Osawa; M Miyata; H Inuma; T Sasaki; M Kaizuka; N Tamura
Journal:  J Am Soc Nephrol       Date:  1995-08       Impact factor: 10.121

9.  Glomerulonephritis after ventriculo-atrial shunt.

Authors:  J Vella; M Carmody; E Campbell; O Browne; G Doyle; J Donohoe
Journal:  QJM       Date:  1995-12

10.  Acute renal failure due to mesangial proliferative glomerulonephritis in a pregnant woman with primary Sjögren's syndrome.

Authors:  Fatma Ulku Adam; Dilek Torun; Filiz Bolat; Aysegul Zumrutdal; Siren Sezer; Fatma Nurhan Ozdemir
Journal:  Clin Rheumatol       Date:  2005-05-26       Impact factor: 3.650

View more
  67 in total

1.  Eculizumab for dense deposit disease and C3 glomerulonephritis.

Authors:  Andrew S Bomback; Richard J Smith; Gaetano R Barile; Yuzhou Zhang; Eliot C Heher; Leal Herlitz; M Barry Stokes; Glen S Markowitz; Vivette D D'Agati; Pietro A Canetta; Jai Radhakrishnan; Gerald B Appel
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

2.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Authors:  Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

3.  Secondary focal and segmental glomerulosclerosis associated with single-nucleotide polymorphisms in the genes encoding complement factor H and C3.

Authors:  Sanjeev Sethi; Fernando C Fervenza; Yuzhou Zhang; Richard J H Smith
Journal:  Am J Kidney Dis       Date:  2012-05-16       Impact factor: 8.860

4.  Membranoproliferative glomerulonephritis: the times they are a-changin'.

Authors:  Jan Willem Cohen Tervaert
Journal:  Clin Exp Nephrol       Date:  2013-08-28       Impact factor: 2.801

Review 5.  The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases.

Authors:  Sanjeev Sethi; S Vincent Rajkumar; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2018-04-27       Impact factor: 10.121

6.  Rituximab fails where eculizumab restores renal function in C3nef-related DDD.

Authors:  Caroline Rousset-Rouvière; Mathilde Cailliez; Florentine Garaix; Daniele Bruno; Daniel Laurent; Michel Tsimaratos
Journal:  Pediatr Nephrol       Date:  2014-01-10       Impact factor: 3.714

7.  Circulating complement levels and C3 glomerulopathy.

Authors:  Fernando C Fervenza; Sanjeev Sethi
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-23       Impact factor: 8.237

8.  C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?

Authors:  Mariam P Alexander; Fernando C Fervenza; An S De Vriese; Richard J H Smith; Samih H Nasr; Lynn D Cornell; Loren P Herrera Hernandez; Yuzhou Zhang; Sanjeev Sethi
Journal:  J Nephrol       Date:  2015-07-18       Impact factor: 3.902

9.  C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; Sanjeev Sethi
Journal:  Kidney Int       Date:  2018-05-03       Impact factor: 10.612

10.  C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; An S De Vriese; Sanjeev Sethi
Journal:  Mayo Clin Proc       Date:  2018-08       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.